Anthony Bergmann sold $732k of CAPR
CHIEF FINANCIAL OFFICER at CAPRICOR THERAPEUTICS, INC.. 24,100 shares at an average of $30.38, traded Jun 25, 2026, filed Jun 29, 2026.
Score components
- +22RoleCFO
- +21Trade size$732k at market
- +20Share of holdings soldSold 68% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001593087-26-000013, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 25, 2026 | MOption exercise Common Stock | +24,100 | $3.18 | $77k | 35,323 | Jun 29, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stock10b5-1 | -24,100 | $30.38 | $732k | 11,223 | Jun 29, 2026 |
| Jun 25, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -24,100 | $0.00 | $0 | 91,980 | Jun 29, 2026 |
Related signals
Other insiders at CAPRICOR THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | CAPRICOR THERAPEUTICS, INC. | Karen Krasney EVP, GENERAL COUNSEL | $732k 24,100 shares | -44% | |
| 0Weak | CAPRICOR THERAPEUTICS, INC. | Anthony Bergmann CHIEF FINANCIAL OFFICER | $27k 900 shares | -8% | |
| 0Weak | CAPRICOR THERAPEUTICS, INC. | Karen Krasney EVP, GENERAL COUNSEL | $27k 900 shares | -3% | |
| 37Weak | CAPRICOR THERAPEUTICS, INC. | Anthony Bergmann CHIEF FINANCIAL OFFICER | $793k 25,000 shares | -75% | |
| 20Weak | CAPRICOR THERAPEUTICS, INC. | Karen Krasney EVP, GENERAL COUNSEL | $793k 25,000 shares | -45% | |
| 28Weak | CAPRICOR THERAPEUTICS, INC. | Karimah Es Sabar director | $241k 7,529 shares | -100% | |
| 44Moderate | CAPRICOR THERAPEUTICS, INC. | Anthony Bergmann CHIEF FINANCIAL OFFICER | $753k 25,000 shares | -75% | |
| 27Weak | CAPRICOR THERAPEUTICS, INC. | Karen Krasney EVP, GENERAL COUNSEL | $753k 25,000 shares | -45% | |
| 40Moderate | CAPRICOR THERAPEUTICS, INC. | Karimah Es Sabar director | $3.5M 115,000 shares | -188% | |
| 46Moderate | CAPRICOR THERAPEUTICS, INC. | David B Musket director | $1,128 410 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.